Propranolol-resistant infantile haemangiomas.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 23659587.
- Also identified by DOI 10.1111/bjd.12417.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Propranolol is now widely used to treat severe infantile haemangiomas (IHs). Very few cases of propranolol-resistant IH (PRIH) are mentioned in the literature. To describe the characteristics of PRIHs. A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible. Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0.9%) had PRIHs. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage. PRIH is a rare phenomenon that raises questions and merits further investigation.
Medical subject headings
- Antineoplastic Agents
- Facial Neoplasms
- Hemangioma
- Orbital Neoplasms
- Propranolol
- Skin Neoplasms